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Abstract: Endocrine disruptors (EDs) are compounds used in various industrial products, 
drugs, and cosmetics. They can be found in the environment and disturb the endocrine and 
reproductive systems, resulting in adverse effects to humans and wildlife such as birth 
defects and developmental disorders. Since several EDs have a structure similar to that of 
endogenous steroid hormones such as estrogens, they intend to have an affinity for steroid 
hormone receptors and alter hormone-mediated metabolism by binding to these receptors. 
EDs are therefore a global concern and assays should be developed to efficiently determine 
whether these compounds are detrimental to biological systems. Diverse experimental 
methods may help determine the endocrine disrupting potential of EDs and evaluate the 
adverse effects of a single and/or combination of these reagents. Currently, biomarkers 
have been employed to objectively measure EDs potency and understand the underlying 
mechanisms. Further studies are required to develop ideal screening methods and 
biomarkers to determine EDs potency at environmentally relevant concentrations. In this 
review, we describe the biomarkers for estrogenicity of EDs identified both in vitro and  
in vivo, and introduce a biomarker, cabindin-D9k (CaBP-9k), that may be used to assess 
estrogenic activity of EDs. 
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1. Introduction 
Endocrine disruptors (EDs) are environmental chemicals that disrupt the endocrine system of 
wildlife and humans. Studies performed in the 1930s showed that a number of synthetic chemicals 
have estrogenic properties, and the feminizing effect of the pesticide dichlorodiphenyltrichloroethane 
(DDT) was demonstrated in roosters in the 1950s [1,2]. Hormonally active chemicals, (i.e., 
diethylstilbestrol or DES) were widely used to prevent abortions until 1971; however, vaginal clear cell 
carcinogenesis was observed in young women due to use of synthetic estrogen during pregnancy [3]. 
Furthermore, female offspring from women who were exposed to DES had an increased risk of 
reproductive and immunologic abnormalities, and male offspring were at risk for genital anomalies and 
abnormal spermatogenesis [4,5]. It was also reported that EDs potentially cause fetal pathophysiology, 
abnormal maturation of the brain, learning disabilities, disorders associated with attention, motivation, 
emotion and cognitive development. In addition, reduction of sperm count and prostate enlargement in 
males; ovarian and uterine dysfunctions in females have been reported [6,7]. These findings indicate 
that hormonal disruption caused by EDs in animals and humans results in serious adverse effects. 
EDs are widely found in drugs, pesticides, and compounds used for manufacturing plastics (see 
Table 1). Most EDs have a structure similar to that of endogenous steroid hormones and primarily act 
through nuclear hormone receptors including estrogen receptors (ERs), androgen receptors (ARs), and 
thyroid receptors (TRs) [8]. Having a structure similar to that of hormones permits EDs to exert 
abnormal effects that disrupt endocrine systems through diverse pathways including binding to hormone 
receptors, mimicking hormone action, and blocking the action of hormones [9-11]. Estrogen (E2) is 
hormone essential for the development of reproductive organs, bone, liver, and the cardiovascular 
system, and plays an important role in many physiological processes [12]. Diverse types of EDs have 
been shown to have estrogenic activity because of high binding affinity for ERs. ERs are steroid 
hormone nuclear receptors and act as ligand-activated transcription factors. ERs have two isoforms, 
ER-α and ER-β, which can bind a wide variety of EDs and activate the transcription of estrogen-
responsive genes [13,14]. However, there are no standard methods to determine whether certain EDs 
have an estrogenic activity or not. In this review, we discuss diverse methods to evaluate EDs and 
discuss the use of CaBP-9k as a biomarker for identifying estrogenic EDs. 
Table 1. List of estrogenic EDs. 
Chemical Class  EDs  References 
Industrial byproducts  Polychlorinated biphenyls (PCBs)   
  Polybrominated biphenyls (PBBs)   
 Dioxins  [15,16] 
Plastics  Bisphenol A (BPA)  [17,18] 
Plasticizers Phthalates  [19,20] 
Pesticides Methoxychlor   
 Chlorpyrifos   
 Dichlorodiphenyltrichloroethane  [21,22] 
Fungicides Vinclozolin  [23,24] 
Pharmaceutical agents  DES  [3,5] 
Biodegradation products  Octyl-phenol (OP)   
 Nonylphenol  (NP)  [25,26] 
Phytoestrogens Genistein   
 Coumestrol  [24,27,28] Int. J. Environ. Res. Public Health 2012, 9          
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2. Biomarkers for Measuring the Estrogenic Effect of EDs 
2.1. Vitellogenin 
Vitellogenin (VTG) is an egg yolk precursor protein and is normally produced by liver cells of 
female fish in response to E2 secreted by the pituitary gland [29]. It is released into the blood where it 
circulates until it reached the ovaries and promotes oocyte development. Male fish also carry the VTG 
gene, although VTG protein is normally not expressed because the circulation levels of E2 are 
extremely low in male blood plasma [30]. However, males still have the capability to express VTG, 
and male fish are known to produce the protein under the influence of estrogenic EDs [30-32]. E2, NP, 
and OP all induce the expression of VTG in male fish in a dose-dependent manner [33,34], suggesting 
that the VTG gene in male fish can be used as a biomarker for evaluating the effects of EDs [35-37].  
2.2. Complement C3 and Ornithine Decarboxylase 
The uterus is a general target organ for estrogen-mediated metabolism. A uterotrophic bioassay is 
widely used to measure increased uterine wet weight after EDs treatment [38]. However, this assay 
does not evaluate effects other than those associated with the estrogenic activity of EDs which could 
lead increased uterine weight via unknown pathways. In the past few years, several genes regulated in 
the uterus have been identified and used as marker genes to assess the estrogenicity of EDs. For 
example, genes for the gap junction connexin, such as connexin 26 and connexin 43, the plasma 
glycoprotein clusterin, and complement C3 were shown to be highly regulated by E2 in rat 
endometrium [39-41].  
Complement C3, simply called C3, is a protein involved in the immune system which plays a 
central role in activating complement pathways and promotes innate immunity [42]. In adult female 
mice, C3 is exclusively expressed in the uterus. E2 administration to immature or ovariectomized mice 
significantly increases C3 mRNA levels as well as immunoreactivity in the endometrium, indicating 
that the synthesis of this protein is regulated by E2 in mouse endometrium [43]. Phyto- and 
xenogestogens have been found to induce C3 expression in endometrium, and the sensitive parameter 
of C3 is highly suited to investigate the biological potential of natural and synthetic estrogens [39].  
The enzyme ornithine decarboxylase catalyzes the decarboxylation of ornithine (a product of the 
urea cycle) to form putrescine, which is the committed step in polyamine synthesis [44]. The rapid 
growth and differentiation of uterus are concomitant with increased expression of the ornithine 
decarboxylase gene. Recent studies have shown that expression of ornithine decarboxylase gene in the 
uterus is augmented by EDs [45-48].  These estrogen-sensitive genes have therefore been used as 
markers for evaluating the estrogenic potential of EDs in the uterus 
2.3. pS2 and Mucin 1 
pS2 is a low molecular weight protein containing 60 amino acid. E2 and estrogenic compounds 
stimulate the expression of pS2 which was first observed in the MCF-7 breast cancer cell line into 
which the pS2 gene has been cloned [49]. pS2 mRNA production can be rapidly induced by E2 in 
certain breast cancers, but not in normal breast tissue nor in any other human cell lines. Therefore,  Int. J. Environ. Res. Public Health 2012, 9          
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pS2 mRNA expression in MCF-7 cells is an ideal model for studying the effects of estrogenic 
compounds [49-51].  
Cell surface mucins are a family of highly glycosylated glycoproteins found in the apical cell 
membranes of epithelial cells from the mammary gland, salivary gland, respiratory tract, digestive 
tract, uterus, and testis [52,53]. Mucin1 (MUC1), a mucin and well-known marker of breast cancer, is 
an extended rod-like molecule which protrudes above the cell surface of epithelial cells [54]. The 
MUC1 promoter region has half of an estrogen response element (ERE) and is regulated by E2. 
Therefore, MUC1 is known to be a direct E2 target gene due to specific ER binding in MCF-7   
cells [55]. EDs, including NP, have been reported to induce the expression of pS2 and MUC1 in  
MCF-7 breast cancer cells [54].  
2.4. Progesterone Receptor  
The progesterone receptor (PR) is an intracellular steroid receptor that specifically binds to 
progesterone and is involved in a wide variety of physiological functions including the control of 
embryonic development, cell differentiation, and homeostasis [56-58]. The PR gene is a known target 
of E2 in certain cell lines including MCF-7 and GH3 cells that express ERs [59,60]. Recent studies 
have observed EDs-induced expression of PRs in GH3 rat pituitary cells. Several parabens and E2 
significantly increased PR expression in these cells [60], demonstrating that PR levels may be 
augmented by EDs through an ER-mediated pathway in GH3 cells [61,62]. By measuring the expression 
levels of VTG, Complement C3, ornithine decarboxylase, pS2, MUC1 and PR genes, EDs estrogenicity 
can be efficiently evaluated in a cost- and time-effective manner.  
3. CaBP-9k Gene Expression as a Biomarker for Assessing the Effects of EDs 
3.1. Introduction of the CaBP-9k Gene 
Calbindin-D9k (CaBP-9k) is a 9-kDa cytosolic protein and a member of the S100 family of   
calcium-binding proteins that includes calmodulin, paravalbumin, troponin C, and calbindin-D28k. 
These calcium-binding proteins were recently classified into different sub-families as they differ in the 
number of calcium-binding EF-hand sites [63,64]. CaBP-9k has two calcium-binding domains that 
have high affinities for calcium. The CaBP-9k gene is localized on the X chromosome and consists of 
three exons interrupted by two introns [65,66]. The CaBP-9k protein is composed of 79 amino acids. 
The C-terminal site (amino acids 54–65) is a normal EF-hand similar to that found in other proteins of 
the S100 family while the N-terminal site (amino acids 14–27) has a unique structure containing different 
amino acids. However, N-terminal site have not disrupted the calcium binding ability of CaBP-9k [67].  
3.2. Regulation of CaBP-9k Gene Expression 
CaBP-9k is an intracellular factor primarily known as a vitamin D-dependent calcium-binding 
protein found in the cytoplasm of intestinal cells [68,69]. CaBP-9k expression has been reported   
in intestine, kidneys, bone, lung, placenta, pituitary gland, and uterus [70]. Duodenal and renal   
CaBP-9k are involved in calcium absorption and re-absorption; its expression is regulated by   
1,25-dihydroxyvitamin D3 [71,72]. Duodenal CaBP-9k is mainly expressed in enterocytes of the Int. J. Environ. Res. Public Health 2012, 9          
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duodenum in rodents and is involved in intestinal calcium absorption [73]. Additionally, the level of 
CaBP-9k mRNA is thought to be a marker of small intestine differentiation [74,75]. Renal CaBP-9k 
plays a role in calcium re-absorption in the kidney, which is important for maintaining calcium 
homeostasis in the body. Ionized and calcium enters the glomerular filtrate by convection and is   
re-absorbed by the renal tubules [72]. Renal CaBP-9k is expressed at the site of calcium re-absorption 
and localized in the distal convoluted tubules in rodents [76,77].  
The regulation of CaBP-9k expression in other tissues other than duodenum and kidney is known to 
be accomplished through different mechanisms. For instance, uterine CaBP-9k is not under the control 
of 1,25-dihydroxyvitamin D3 despite the presence of 1,25-dihydroxyvitamin D3 receptors [78]. 
Uterine CaBP-9k is expressed mainly in the endometrial stroma and myometrium in non-pregnant 
rodents and regulated by sex steroid hormones [79,80]. An estrogen response element (ERE) in   
the CaBP-9k promoter mediates transcriptional regulation of CaBP-9k in the presence of E2 in rat 
uterus [81]. On the other hand, a progesterone response element (PRE) in the CaBP-9k promoter is 
responsible for responsiveness to progesterone (P4) in mouse uterus [82]. Interestingly, uterine CaBP-9k 
is up-regulated by E2 and down-regulated by P4 during the estrous cycle in rat uterus [83,84], while it 
has been shown to be decreased by E2 in mouse uterus [85-87]. 
3.3. In Vivo Evaluation of Estrogenic Activity of EDs Using the CaBP-9k Gene 
Recently, CaBP-9k was suggested to be a novel biomarker for evaluating EDs activity [88,89]. 
CaBP-9k expression levels increased by exposure to EDs are considered to be effective tools for 
screening estrogenic compounds in in vivo models. Recent studies demonstrated that estrogenic 
compounds significantly increase the expression of uterine CaBP-9k in rats [78]. An et al. showed that 
E2, OP, NP, and BPA increased uterine CaBP-9k gene expression in rats. Furthermore, these estrogenic 
compounds also significantly increase uterine weight in rats [84,89]. Estrogenic compounds, which 
form a class of EDs that includes diethylstilbestrol [90], tetrabromodiphenyl ether [91], phthalates [92] 
genistein [93], and parabens [94], strongly induce uterine CaBP-9k mRNA and protein expression in 
the uterus of rats. Moreover, the ER antagonist ICI 182,780 prevents increased expression of uterine 
CaBP-9k when co-administered with estrogenic compounds. It has been confirmed that ER-mediated 
signaling is involved in the induction of CaBP-9k gene expression by estrogenic compounds [95]. 
These findings suggest that the CaBP-9k gene is a useful biomarker gene for assessing the estrogenic 
potential of EDs. 
The ability of CaBP-9k for evaluating EDs in an in vivo system is summarized in Table 2. 
Triclosan, tetrabromodiphenyl ether 47 (BDE47), and genistein at concentrations less than 50 mg/kg 
have been found to have regulatory effects on uterine CaBP-9k expression [91,93]. Triclosan at a dose 
of 37.5 mg/kg up-regulates uterine CaBP-9k expression in an immature rat model [96]. Genistein has 
similar potential with triclosan at dose of 40 mg/kg. Treatment with BDE47 (50 mg/kg) led a significant 
increase in uterine CaBP-9k as determined by RT-PCR. OP, NP, and BPA (600 mg/kg) induce uterine 
CaBP-9k expression at in the rat; however, lower concentrations (100 to 250 mg/kg) of these 
compounds had a more prominent effect in mice [84]. Methoxychlor (250 mg/kg) was reported to have 
a moderate effect on CaBP-9k expression in rat uterus [97]. Butyl benzyl phthalate (BBP), dicyclohexyl 
phthalate (DCHP), 2-ethylhexyl phthalate (DEHP), di-n-butyl phthalate (DBP), and diethyl phthalate Int. J. Environ. Res. Public Health 2012, 9          
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(DEP) do not have any significant estrogenic effects on CaBP-9k gene expression in rat uterus [92]. 
Changes in CaBP-9k expression for assessing EDs activity are sufficient when compared to other 
biomarkers. For example, C3, a well-known biomarker for measuring EDs effects, shows a level of 
sensitivity similar to that of CaBP-9k at a concentration in the presence of OP and BPA (200 mg/kg) [40].  
Table 2. Expression of uterine CaBP-9k in in vivo system by different EDs concentrations. 
Endocrine disruptors 
Doses 
(mg/kg) 
Animal Route  Method  Reference 
Triclosan 37.5  rat  Oral  q-PCR/western  [96] 
Genistein 40  rat  S.C  injection  Western  [93] 
Tetrabromodiphenyl ether 47  50  rat  S.C injection  RT-PCR  [91] 
Octyl phenol  100/600  mouse/rat S.C injection  Western  [84] 
Methoxychlor 200  rat  Oral  Northern  [97] 
Nonyl phenol  250/600  mouse/rat S.C injection  Western  [84] 
Bisphenol A  250/600  mouse/rat S.C injection  Western  [84] 
3.4. In Vitro Evaluation of Estrogenic Activity of EDs Using the CaBP-9k Gene 
In 2004, Fujimoto et al. identified estrogen-responsive genes in the rat pituitary GH3 cell line [98]. 
GH3 cells were initially characterized as ones that can synthesize growth hormone and prolactin (PRL) 
in response to E2 stimulation [99]. It was suggested that the GH3 cell line is a good candidate for 
assessing the in vitro estrogenicity of EDs since it is E2-sensitive and expresses functional ERs [98]. 
Recent studies have reported that EDs induce CaBP-9k expression in this cell line. OP, NP, and BPA 
induce a significant increase in CaBP-9k expression in GH3 cells in addition to augmenting growth 
hormone and PRL production and gene expression [100]. Moreover, activation of extracellular   
signal-regulated kinases (ERKs), protein kinases B (Akt), or G proteins by OP, NP and BPA has been 
observed in these cells [99,100]. Significant induction in CaBP-9k and PR gene expression was also 
observed after treatment with various concentrations of parabens [61]. In this study, the effects of 
parabens on the regulation of CaBP-9k expression were blocked in the presence of ICI 182,780, 
indicating that CaBP-9k is induced by EDs via the ER pathway in GH3 cell line.  
Evaluation of the CaBP-9k gene as a biomarker for EDs activity in in vitro systems is summarized 
in Table 3. OP, isobutyl phenol, and ethyl- and isobutyl parabens produce the strongest induction of 
CaBP-9k expression at a concentration of 0.1 μM in GH3 cells, while NP and isopropyl- and   
butyl-parabens increase CaBP-9k gene expression at a concentration of 1 μM [100]. The concentration of 
BPA and methyl-and propyl-parabens required for inducing CaBP-9k gene expression is 10 μM [61]. 
The efficiency of CaBP-9k gene for EDs effect was sensitive than other genes, since pS2, ER and 
MUC1 were induced at 10 μM of NP in human breast MCF-7 cells, although the cell lines and other 
experimental conditions were different [54].   
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Table 3. Expression of CaBP-9k on in vitro system under different EDs concentration. 
Endocrine disruptors 
Minimum 
concentration (μM) 
Method Reference 
Octyl phenol  0.1  q-PCR  [62] 
Ethyl paraben  0.1  q-PCR  [101] 
Isobutyl paraben  0.1  q-PCR  [101] 
Nonyl phenol  1  RT-PCR  [100] 
Isopropyl paraben  1  q-PCR  [101] 
Butyl paraben  1  q-PCR  [101] 
Bisphenol A  10  RT-PCR  [100] 
Methyl paraben  10  q-PCR  [101] 
Propyl paraben  10  q-PCR  [101] 
The sensitivity of the CaBP-9k gene for assessing estrogenic activity of EDs compared to other 
biomarkers is difficult to define because effect of intermediate concentrations (i.e., OP: 0.01–1 μM) of 
EDs have not been tested, particularly in in vivo models. However, the CaBP-9k  gene has been 
evaluated as a biomarker for EDs activity by a number of in vivo and in vitro studies as described 
above. Taken together, data from these studies have demonstrated that the CaBP-9k gene is a sensitive 
and valuable biomarker for assessing the potential estrogenic activity of EDs. 
4. Conclusions  
EDs are natural or synthetic chemicals with structures similar to those of endogenous hormones and 
have been shown to disrupt endocrine, nervous, and reproduction systems in animals and humans. 
There are growing concerns about health problems associated with exposure to EDs found in the 
environment. Chemicals that disrupt the endocrine system have been shown to have a high binding 
affinity to steroid hormone receptors, suggesting that exposure to EDs can seriously impact metabolism, 
development, reproduction, and behavior in mammals, including humans. Therefore, identification and 
characterization of EDs is urgent for predicting their detrimental effects. Efficient and accurate assays 
are required to measure EDs potency and to determine what chemicals can possibility be defined as 
EDs. However, methods for detecting the adverse effects of EDs are still limited. There are currently 
no sufficient standard biomarker systems or precise methods for evaluating the effects of EDs. Further 
research to determine the physiological concentration of various EDs (administered alone or in 
combination) necessary for disturbing biological systems and exerting adverse effects on human health 
is required. In this review, we discussed the properties of the CaBP-9k gene and its potential use as a 
biomarker for EDs activity. However, further studies to examine the accumulated, synergistic, and 
addictive effect of EDs using this biomarker are needed. In addition, identification of novel biomarkers 
that can determine the biologically and physiologically relevant concentrations of EDs is necessary.  
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